isocarboxazid has been researched along with Adverse Drug Event in 3 studies
Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)
Excerpt | Relevance | Reference |
---|---|---|
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M | 1 |
Vijay, V | 1 |
Shi, Q | 2 |
Liu, Z | 2 |
Fang, H | 2 |
Tong, W | 2 |
Ding, D | 1 |
Kelly, R | 1 |
Lipman, RS | 1 |
Uhlenhuth, EH | 1 |
Rickels, K | 1 |
Covi, L | 1 |
1 trial available for isocarboxazid and Adverse Drug Event
Article | Year |
---|---|
Medication attitudes and drug response.
Topics: Anorexia Nervosa; Anxiety; Atropine; Attitude; Attitude of Health Personnel; Clinical Trials as Topi | 1969 |
2 other studies available for isocarboxazid and Adverse Drug Event
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |